INCIDENCE AND ASSOCIATED FACTORS WITH THE CHANGE FREE TIME BETWEEN THE BRANDED OR GENERIC IMATINIB IN NAIVE PATIENTS WITH CHRONIC MYELOID LEUKEMIA